Loading
Life sciences · Journal article
BMC Endocrine Disorders · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Although previous studies have reported some association between Netrin-4 (NTN4) and obesity, its association with other metabolic disorders remains unknown. The aim of this study was to explore the associations of Netrin-4 with insulin resistance (IR) and metabolic disorders in polycystic ovary syndrome (PCOS) women and the normal population. The current study was comprised of a cross-sectional study and a series of interventional studies. Circulating NTN4 and adiponectin levels were determined using ELISA kits. Hyperinsulinemic-euglycemic clamps and oral glucose tolerance tests were conducted in all subjects. 137 PCOS women were given anti-insulin resistance treatment for 24 weeks. Transcriptome sequencing data of abdominal subcutaneous adipose stem cells in PCOS women were downloaded for differentially expressed gene (DEG) analysis. Bioinformatics analysis found that genes and signaling pathways related to NTN4 were mainly associated with fatty acid metabolism. Circulating NTN4 levels were elevated in PCOS and IR subjects and exhibited a significant correlation with various metabolic and androgen indices. Among the three treatment groups, only GLP‑1RA reduced circulating NTN4 levels, and this effect appeared to be independent of its insulin‑sensitizing effect. Our results have reinforced the hypothesis that NTN4 may be a biomarker and potential pharmacological target in the management and understanding of IR and PCOS. ChiCTR-OOC-14,005,314. Date of registration: September 16, 2014.